# **Screening Libraries**

# **IBT6A**

Cat. No.: HY-13036A CAS No.: 1022150-12-4 Molecular Formula:  $C_{22}H_{22}N_{6}O$ 386.45

Molecular Weight: Btk Target:

Pathway: Protein Tyrosine Kinase/RTK

Storage: Powder -20°C 3 years

2 years -80°C In solvent 2 years

> -20°C 1 year

**Product** Data Sheet

# **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 50 mg/mL (129.38 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.5877 mL	12.9383 mL	25.8766 mL
	5 mM	0.5175 mL	2.5877 mL	5.1753 mL
	10 mM	0.2588 mL	1.2938 mL	2.5877 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (6.47 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

Description	IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct <sup>[1]</sup> . Ibrut	
	selective, irreversible Btk inhibitor with an IC <sub>50</sub> of 0.5 nM <sup>[2]</sup> .	

IBT6A (Compound 14) can be used in synthesis of Ibrutinib and Ibrutinib-based activity-based probes (ABPs)<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vitro

## **REFERENCES**

- [1]. Liu N, et al. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Org Biomol Chem. 2015 May 14;13(18):5147-57.
- [2]. Somana Siva Prasad, et al. A QUALITY BY DESIGN APPROACH FOR DEVELOPMENT OF SIMPLE AND ROBUST REVERSED PHASE STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF IBRUTINIB AND ITS IMPURITIES.
- [3]. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com